A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, or Basal Insulin, or Both
Latest Information Update: 06 Mar 2025
At a glance
- Drugs Tirzepatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms SURPASS-PEDS
- Sponsors Eli Lilly and Company
Most Recent Events
- 26 Feb 2025 Status changed from active, no longer recruiting to completed.
- 10 Apr 2024 Planned End Date changed from 31 Dec 2024 to 1 Feb 2025.
- 10 Apr 2024 Planned primary completion date changed from 30 Nov 2024 to 1 Aug 2024.